Janssen-Cilag Polskasp. z o.o.Status: Entity active

Advertising agencies

KRS: 0000143626 NIP: 5222665719 REGON: 01529633900000

Overview

Registry date

2002-12-17

Share capital

$6,766,612.64

Activity description

Janssen-Cilag Polska is a pharmaceutical company that focuses on innovative medicine, particularly in oncology, immunology, and neuroscience. It has developed and received FDA approval for several treatments, including RYBREVANT FASPRO™ for EGFR-mutated non-small cell lung cancer, CAPLYTA® for major depressive disorder, and DARZALEX FASPRO® for high-risk smoldering multiple myeloma. The company also acquired Halda Therapeutics to enhance cancer treatment options.

Registered address

Iłżecka 24, 02-135 Warszawa, Poland

Website

janssen.pl

Industry

Name	Code
Advertising agenciesPrimary	73.11.Z
Other research and experimental development on natural sciences and engineering	72.19.Z
Market research and public opinion polling	73.20.Z
Public relations and communication activities	70.21.Z
Business and other management consultancy activities	70.22.Z

Authorized Representatives

Ownership

Competitors

Name	Revenue	Website
CUBE GroupS.A.	$14,244,022.30	cubegroup.pl
Domodisp. z o.o.	$12,618,800.75	domodi.pl
Unique Onesp. z o.o.	$10,199,051.62	uniqueone.pl
AWEBsp. z o.o.	$9,981,888.00	aweb.agency
Feelgoodsp. z o.o.	$8,945,125.78	feelgood.pl
ARS ThaneaS.A.	$8,908,279.63	arsthanea.com/
Pikseo Rafał Łapkasp. k.	$8,779,786.27	pikseo.pl
Goldensubmarinesp. z o.o. + limited partnership	$8,424,611.63	goldensubmarine.com
Bedigitalsp. z o.o.	$8,128,445.75	bedigital.pl
Active.Plsp. z o.o. + limited partnership	$7,411,417.69	active.pl

Change history

	Event	Details	Date
	Name change	J-c Polska → Janssen-Cilag Polska	2025-12-16
	PKD change	Removed: 72.30.Z, 73.10.F, 74.13.Z, 74.14.A, 74.40.Z, 74.84.B	2025-12-16

Last updated: 2026-04-07